HC Wainwright & Co. Reiterates Buy on Disc Medicine, Maintains $70 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating for Disc Medicine (NASDAQ:IRON) and maintained a price target of $70.
October 28, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for Disc Medicine, maintaining a $70 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $70 price target by a reputable analyst suggests a positive outlook for Disc Medicine, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100